Title
A Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate in Lateral Epicondylitis (Tennis Elbow)
A Prospective, Multicentric, Open Label, Randomised, Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For The Treatment Of Lateral Epicondylitis (Tennis Elbow)
Phase
Phase 1/Phase 2Lead Sponsor
Bharat Biotech International LimitedStudy Type
InterventionalStatus
Unknown statusIndication/Condition
Lateral Epicondylitis (Tennis Elbow)Intervention/Treatment
betamethasone platelet-rich plasma ...Study Participants
20This is a multicentre, open label, randomized, pilot study to evaluate safety and efficacy of human Platelet Lysate (HPL) in subjects with Lateral Epicondylitis (Tennis Elbow). The study is being conducted in 2 centers in India. The primary end points are Visual Analog Score (VAS) and Patient rated tennis elbow evaluation (PRTEE) score. The secondary endpoint is improvement in ultrasonography form randomization to End of study.
Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
Subjects will receive one injection of Autologous Human Platelet lysate in the lateral epicondyle space
Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
Inclusion Criteria: Subjects with clinical diagnosis of tennis elbow within the last 3 months Subjects both male and female, aged 18-60 years (both inclusive) Subjects who are willing to give informed consent and adhere to the study protocol Exclusion Criteria: Subjects aged less than 18 and more than 60 years Subjects with autoimmune diseases Subjects with immuno-compromised system Subjects on Anti-coagulant therapy or blood thinning medicines like Aspirin Subjects taking concomitant therapy that might interfere with the study results in investigators opinion or who had concomitant other injury of the tennis elbow tendons. Subjects who have received treatment with corticosteroid injections within the last 6 months